Sentences with phrase «year duration of the fund»

In the Vanguard study the 5.5 year duration of the fund meant that for a 1 % increase in yields you would expect the price to fall by roughly 5.5 %.

Not exact matches

For example, Dodge & Cox Income fund, with a duration of around four years, lost 0.9 percent in the first quarter.

While the CCA declares on its website that it doesn't lobby for policies that determine «the basis for or duration of an individual's incarceration or detention,» the Justice Policy Institute has documented several pieces of federal legislation the CCA lobbied on in recent years, including funding related to private prisons and Immigrations and Customs Enforcement (ICE) detention.

On Money magazine's MONEY 50 recommended list, Vanguard Short - Term Investment Grade (VFSTX) has a duration of 2.6 years, implying if rates were to rise one full point, the price of the fund's holdings would decline 2.6 %.

The average duration of the fund is 2.48 years, and management fees are 0.25 %.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

To be sure, the typical core bond fund sports a duration of around five years.

After the investment period has ended, the fund legally is not allowed to make new investments, it should be spending the remainder of the fund duration (funds are usually ten years long with a few one year extensions) harvesting its investments for liquidity.

Take an intermediate bond fund with a duration — interest rate sensitivity — of six years.

«A fund with a duration of six and a half years will lose principal value of approximately 6.5 percent for every 1 percent increase in long - term interest rates,» Scott said.

The Pimco 25 + Year Zero Coupon U.S. Treasury Fund (NYSEArca: ZROZ) gained 4.68 percent in the five - day trading period, while the Vanguard Extended Duration Treasury ETF (NYSEArca: EDV), now a $ 213.9 million fund, tagged on gains of 4.6 percent on the wFund (NYSEArca: ZROZ) gained 4.68 percent in the five - day trading period, while the Vanguard Extended Duration Treasury ETF (NYSEArca: EDV), now a $ 213.9 million fund, tagged on gains of 4.6 percent on the wfund, tagged on gains of 4.6 percent on the week.

We sold a portion of our Treasury inflation protected securities on the advance, moving the overall duration of the Strategic Total Return Fund to about 2.3 years.

While we would be inclined to increase the duration of the Strategic Total Return Fund modestly if the 10 - year Treasury yield was to push beyond 4 % or so, we are comfortable with our current duration of just under 4 years.

The Strategic Total Return Fund currently carries a duration of about 2 years, primarily in U.S. Treasury securities, with just over 15 % of assets allocated to foreign currencies.

The Strategic Total Return Fund currently has an overall duration slightly over 3 years, primarily in straight Treasuries, with a small 1 % exposure to precious metals shares and about 4 % of assets in utility shares.

Under normal market conditions, the duration of the Fund's portfolio is expected to range between 1 year and 15 years.

Equities are essentially 50 - year duration investments at current valuations, and even if investors are passive and don't hold any view about future market returns at all, one of the basic principles of financial planning is to align the duration of ones assets with the expected horizon over which the funds are expected to be spent.

The fund has no targeted maturity, but does target a duration within 10 % of the Bloomberg Barclays U.S. Corporate Investment Grade Bond Index, which as of the end March was 7.5 years.

As usual, we need not make specific interest rate forecasts - the fact that prevailing valuations and market action are unfavorable is sufficient to hold the Strategic Total Return Fund to a relatively muted duration of about 2 years, largely in Treasury inflation - protected securities.

In bonds, the Market Climate remains characterized by unfavorable valuations and unfavorable yield pressures, holding the Strategic Total Return Fund to a duration of less than 1 year.

In its most aggressive stance (a duration of 15 years), the Fund's net asset value could be expected to fluctuate by approximately 15 % in response to a 1 % (100 basis point) change in the general level of interest rates.

An intermediate fund with a duration of five years may recover price loss from rising interest rates in about five years.

The Strategic Total Return Fund continues to carry an average duration of about 4 years, primarily in straight Treasuries.

The Strategic Total Return Fund continues to hold a portfolio duration of about 6 years, meaning that a 1 % (100 basis point) change in interest rates would induce a roughly 6 % change in the value of the Fund.

Strategic Total Return continues to carry a duration of about 3.5 years in Treasury securities (meaning that a 100 basis point move in interest rates would be expected to impact the Fund by about 3.5 % on the basis of bond price fluctuations), and holds about 10 % of assets in precious metals shares, and about 5 % of assets in utility shares.

The Strategic Total Return Fund continues to carry a duration of about 2.5 years, mostly in Treasury inflation protected securities, as well as a roughly 8 % position in precious metals shares.

The Strategic Total Return Fund continues to carry a duration of just under 2 years, mostly in Treasury inflation protected securities, and about 20 % of assets in precious metals shares, for which the Market Climate continues to be favorable at present.

I agree it's best to avoid durations that are longer than your time horizon with all bond funds but, in the case of linker funds, your time horizon needs to be under 20 - something years.

If the average real yield of the linker fund goes up 1 % then you lose 23 % but will recover it in 23 years (assuming duration is 23 and no further change in interest rates).

The fidelity global inflation linked bond fund Y has a duration of 5.5 years which seems to be the lowest of the funds freely available.

In the Strategic Total Return Fund, our present duration of about 3.5 years is solidly in Treasury Inflation Protected Securities, which I continue to view as useful investments here.

Given that the Market Climate in bonds continues to be characterized by unfavorable valuations and unfavorable market action, the Strategic Total Return Fund continues to carry a muted duration of about 2 years, mostly in Treasury Inflation Protected Securities.

@Matt — I should leave @TA to comment on his article when he gets a chance, but just quickly the regular Vanguard bond fund in the Slow and Steady portfolio has a duration of 12.3 years versus the index - linked fund's much greater 23.1 year duration.

c) Market - Implied Duration of Growth (Growth Appreciation Period) measures the number of years of future profit growth required to justify the current valuation of the stocks in the fund.

The iShares Barclays 10 - 20 Year Treasury Bond Fund (NYSEArca: TLH) slipped to its lowest price since March 2012, while its longer - duration counterpart, the $ 3 billion iShares Barclays 20 + Year Treasury Bond Fund (NYSEArca: TLT) has erased two years of gains to return to levels not seen since August 2011.

In bonds, yield levels have become somewhat compressed, finally prompting a reduction in our TIPS position to bring the overall duration of the Strategic Total Return Fund to about 1 year.

For now, the Strategic Total Return Fund continues to carry a limited duration of about 2 years (meaning that a 100 basis point move in interest rates would be expected to impact the Fund by about 2 % on the basis of bond price fluctuations), mostly in Treasury Inflation Protected Securities.

In bonds, the Market Climate was characterized by relatively neutral valuations and unfavorable market action, holding the Strategic Total Return Fund to a relatively limited duration of about 2.5 years.

The Strategic Total Return Fund continues to trade around a duration of about 2 years, mostly in Treasury inflation protected securities, with about 20 % of assets in precious metals shares.

«We have been adding some duration exposure to the fund through government bonds since the beginning of the year.

The Strategic Total Return Fund continues to carry a duration of about 4 years, mostly in intermediate term Treasury notes.

Because of their ability to invest in these longer duration securities of slightly less credit quality, stable value funds have outperformed money market funds on average by 150 - 200 basis points (1.50 % -2.00 %) net of fees annually over the past 20 years.

Strategic Total Return continues to carry a duration of about 3 years in Treasury securities (meaning a 100 basis point move in interest rates would be expected to impact Fund value by about 3 % on the basis of bond price fluctuations), with about 10 % of assets in precious metals shares, and about 5 % of assets in utility shares.

(4) gaining exposure to a long - duration growth asset, with AAC having demonstrated internally funded compound growth in the asset base of about 4 per cent a year over the last 15 years; and

Launched in 2003 with government support, NIBS offers its group leaders generous funding for the duration of their 5 - year contracts.

Under the 7th EU Research Framework Programme, the KIT project of three years» duration in the area of information and communication technologies was funded with about EUR 500,000.

Finally, the draft bill includes a new funding programme, the «Descartes Fellowships,» that would reward between 100 and 150 of the best young researchers with approximately 60 % more money than the lowest wage over the award's 5 - year duration.

Research Serv., R42647, Continuing Resolutions: Overview of Components and Recent Practices 1, 13 (2015)(noting that 1997 was the most recent year that the twelve regular appropriations bills that fund the government were all enacted before the end of the fiscal year on October 1 and that since that time, continuing resolutions have been enacted on average six times per fiscal year, for an average duration of almost five months, with full - year continuing resolutions enacted for FY2007, FY2011, and FY2013).

On January 1, 2017 was the official start of the RadioNet, a project with a duration of 4 years that received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 730562.

We also performed subgroup meta - analyses by type of prevention (primary v secondary: in this study, trials involving healthy populations or patients with any specific disease except for cardiovascular disease were classified as primary prevention trials, and trials involving patients with cardiovascular disease were classified as secondary prevention trials), type of supplement by quality and dose (each supplement, vitamins only, antioxidants only, or antioxidants excluding vitamins), type of outcome (cardiovascular death, angina, fatal or non-fatal myocardial infarction, stroke, or transient ischaemic attack), type of outcome in each supplement, type of study design (randomised, double blind, placebo controlled trial v open label, randomised controlled trial), methodological quality (high v low), duration of treatment (< 5 years v ≥ 5 years), funding source (pharmaceutical industry v independent organisation), provider of supplements (pharmaceutical industry v not pharmaceutical industry), type of control (placebo v no placebo), number of participants (≥ 10000 v < 10000), and supplements given singly or in combination with other vitamin or antioxidant supplements by quality.